Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AbbVie’s JAK1 Inhibitor Upadacitinib Hits Primary Endpoints in PIIb/III Study in Japanese RA Patients
May 10, 2018
- Taiho’s Lonsurf Extends OS in PIII in Patients with Metastatic Gastric Cancer
May 10, 2018
- Pfizer Japan Cedes Crown as Top Rep Holder as Global Players Continue to Seek Leaner Sales Force: Survey
May 9, 2018
- Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
May 9, 2018
- Quizartinib Prolongs OS in 2nd-Line AML: Daiichi Sankyo
May 9, 2018
- Daiichi Sankyo, Kaketsuken Terminate Vaccine Sales Partnership
May 9, 2018
- US FDA Approves Myrbetriq/Vesicare Combination Therapy for OAB: Astellas
May 9, 2018
- Kissei Mulls Over Urief AG Launch
May 9, 2018
- MHLW Official Hails Takeda’s Shire Takeover
May 9, 2018
- Takeda Cuts Deal to Acquire Shire in Japan’s Biggest Buyout
May 8, 2018
- Spiolto Improves Lung Function in Japanese COPD Patients against Spiriva in Trial: BI
May 8, 2018
- XLH Drug Crysvita Now Available in US: Kyowa Kirin/Ultragenyx
May 8, 2018
- FDA OKs Label Update for Takeda/Lundbeck’s Trintellix
May 8, 2018
- Over 60% of Drug Makers Cut New Grad Hires in FY2018, Otsuka Tops List Again: Tally
May 8, 2018
- Kyowa Kirin to Focus on New Drugs in Europe, US to Achieve Midterm Targets: New President
May 7, 2018
- Competition Heating Up for HIF-PH Inhibitors; Astellas Expected to Be First with Filing Likely in FY2018
May 7, 2018
- Daiichi Sankyo to Streamline Vaccine Business in April 2019, Setting Up New Manufacturing Company
May 7, 2018
- Japan to Join Jardiance Study for CKD under Collaboration between Boehringer, Lilly, and Oxford
May 2, 2018
- Takeda’s Takeover Bid for Shire “Thought-Provoking”: Daiichi Sankyo CEO
May 1, 2018
- Despite Upbeat AGs, Daiichi Sankyo to Closely Watch Pricing Environment: CEO
May 1, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…